Tumor specific delivery and therapy mediate by integrin β6-target immunoliposomes for β6-siRNA in colon carcinoma.
Adjuvant chemotherapy does not achieve the desired therapeutic efficacy in colon cancer as a result of the deficient reaction. Gene therapy using small interfering RNAs (siRNAs) delivered by target delivering system represents a potent and specific strategy in tumor therapy. Integrinβ6 is exclusively expressed in malignant colonic epithelia, associated with the progression, metastasis, and chemotherapeutic resistance of colon cancer. Accordingly, designing an efficient and targeted delivery system for β6-siRNA could be a potential approach to improve therapeutic efficacy of colon cancer. Here, we designed the Integrinβ6 target immunoliposomes for highly efficient and selective delivery of β6-siRNA in colon cancer, which consequently resulted in greatly growth suppression, invasion and metastasis of colon cancer cells. Moreover, it was able to greatly inhibit the tumor growing in vivo.
Department of Thyroid & Breast Surgery, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China.
Liu
L
Song
Department of Oncology, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China.
Zhang
Z
Fan
Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan 250012, Shandong, PR China.
Niu
N
Jun
Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan 250012, Shandong, PR China.
Liang
L
Benjia
Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan 250012, Shandong, PR China.
Li
L
Zequn
Department of Thyroid & Breast Surgery, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China.
Wang
W
Xilong
Department of Thyroid & Breast Surgery, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China.
Jia
J
Zhongming
Department of Thyroid & Breast Surgery, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China.
Han
H
Yong
Department of Thyroid & Breast Surgery, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China.
Wang
W
Xiaohong
Department of Thyroid & Breast Surgery, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China.
Cheng
C
Kai
Department of Thyroid & Breast Surgery, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China.
Yang
Y
Zhenlin
D000818:Animals; D048708:Cell Growth Processes; D045744:Cell Line, Tumor; D002465:Cell Movement; D003106:Colon / Q000473:pathology*; D003110:Colonic Neoplasms / Q000235:genetics / Q000628:therapy*; D016503:Drug Delivery Systems; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D039641:Integrin beta Chains / Q000235:genetics*; D007413:Intestinal Mucosa / Q000502:physiology*; D008081:Liposomes / Q000138:chemical synthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009362:Neoplasm Metastasis; D034741:RNA, Small Interfering / Q000138:chemical synthesis / Q000235:genetics*; D047368:Tumor Burden; D023041:Xenograft Model Antitumor Assays
D039641:Integrin beta Chains; D008081:Liposomes; D034741:RNA, Small Interfering; C072170:integrin beta6
colon carcinoma; immunoliposomes; integrinβ6; siRNA; target therapy